India CDMO Market Overview
Base Year: 2024
Historical Years: 2019-2024
Forecast Years: 2025-2033
Market Size in 2024: USD 7.9 Billion
Market Forecast in 2033: USD 15.4 Billion
Market Growth Rate: 7.7% (2025-2033)
The CDMO market size in India was valued at USD 7.9 Billion in 2024 and is expected to reach USD 15.4 Billion by 2033, exhibiting a growth rate (CAGR) of 7.7% during 2025-2033.
India CDMO Market Trends:
The Indian CDMO market is undergoing transformations, propelled by global pharmaceutical outsourcing and local manufacturing opportunities in India. One of the dominant trends has been the rise of preference for end-to-end solutions, where CDMOs provide integrated services covering everything from drug development to commercial-scale manufacturing of a drug and thus help cut down on client's time-to-market. Also, the modernization and implementation of technologies like continuous manufacturing and AI is making processes efficient and enhancing product quality so that India turns to a competing global spot.
The rise in biologics and complex generics has also driven the demand for specialized CDMOs that deal with biosimilars and injectables. Strategic collaborations between Indian CDMOs and pharma MNCs are further growing due to cost advantages and regulations vis-à-vis international standards. Actually, regulatory excellence is becoming a key differentiator with Indian companies increasingly getting approvals from stringent agencies such as the US FDA and EMA. Green chemistry and waste reduction initiatives aligning with global ESG norms. Additionally, the expansion of fill-finish capabilities for vaccines and biologics reflects India's strengthened role in global health security post-pandemic.
Request for a sample copy of this report: https://www.imarcgroup.com/india-cdmo-market/requestsample
India CDMO Market Scope and Growth Analysis:
India's CDMO market holds immense growth potential supported by its sturdy pharmaceutical ecosystem with the ever-changing global demand. The market is also getting expanded somewhat by the increasing outsourcing of Big Pharma to lower costs for R&D and to take advantage of India's skilled workforce. Besides, with the government's production-linked incentive (PLI) schemes relating to pharmaceuticals, investments in high-value manufacturing and innovation are getting accelerated. The new drug delivery systems and personalized medicine fields remain largely untapped, offering potential opportunities for CDMOs to expand their service portfolio.
Essentially, the interrelated endogenous healthcare requirements in combination with export-oriented policies create a dual-engine model that balances both local and international demand. Additionally, the market claims its advantage from India having proved to be a heavy-hitter in the global generic drug market, and hence, it is a natural progression that CDMO service providers would cater to off-patent molecules. The coming together of technology and traditional manufacturing puts Indian CDMOs in the sweet spot to be the frontrunners in the next generation therapy arena of cell and gene therapies. Overall, the combination of policy support, technological adoption, and global partnerships ensures sustained growth, solidifying India's role as a key hub for pharmaceutical development and manufacturing.
India CDMO Industry Segmentation:
The report has segmented the market into the following categories:
Service Type Insights:
- Contract Development Services
- Preclinical Development
- Clinical Development
- Analytical and Bioanalytical Services
- Contract Manufacturing Services
- Active Pharmaceutical Ingredients (APIs) Manufacturing
- Finished Dosage Forms (FDFs) Manufacturing
- Biologics Manufacturing
- Packaging
Type Insights:
- Small Molecules
- Biologics
- Biosimilars
- Vaccines
- Others
Scale of Operation Insights:
- Commercial Scale
- Clinical Scale
Therapeutic Area Insights:
- Oncology
- Cardiovascular Diseases
- Infectious Diseases
- Central Nervous System (CNS) Disorders
- Others
Regional Insights:
- North India
- South India
- East India
- West India
Competitor Landscape:
The report offers an in-depth examination of the competitive landscape. It includes a thorough competitive analysis encompassing market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant.
Other key areas covered in the report:
- COVID-19 Impact on the Market
- Porter’s Five Forces Analysis
- Strategic Recommendations
- Market Dynamics
- Historical, Current and Future Market Trends
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain Analysis
- Comprehensive Mapping of the Competitive Landscape
- Top Winning Strategies
- Recent Industry News
- Key Technological Trends & Development
Ask an analyst: https://www.imarcgroup.com/request?type=report&id=30719&flag=C
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-201971-6302